Patents by Inventor Andrena McCavigan
Andrena McCavigan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210254166Abstract: Methods for characterising and/or prognosing cancer in a subject comprise determining the expression level of at least one, and preferably 12, genes selected from Table 1 in a sample from the subject wherein the determined expression level is used to provide a characterisation of and/or a prognosis for the cancer. Determined expression levels are used to generate a signature score. The methods permit metastatic disease to be identified and monitored and guide therapeutic interventions.Type: ApplicationFiled: June 17, 2016Publication date: August 19, 2021Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Steven WALKER, Laura HILL, Andrena MCCAVIGAN, Sinead DONEGAN, Timothy DAVISON, Richard KENNEDY, Denis Paul HARKIN, Bethanie PRICE
-
Patent number: 11091809Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: December 3, 2013Date of Patent: August 17, 2021Assignee: Almac Diagnostic Services LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10280468Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: GrantFiled: February 9, 2015Date of Patent: May 7, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
-
Publication number: 20190127805Abstract: A molecular subgroup of cancer is characterised by misregulation of the MAPK signalling pathway and the epithelial-mesenchymal transition (EMT) pathway. Biomarker signatures can be used to identify cancers within the molecular subgroup. The signatures are also useful for identifying the treatment that is best suited for a given patient. A method for selecting a treatment for a subject having a cancer, comprises measuring the expression level(s) of at least biomarker selected from Table A or Table B in a sample from the subject. By assessing the expression level(s) of the at least 1 biomarker it can be determined whether the sample from the subject is positive or negative for a biomarker signature comprising the at least 1 biomarker. Based on the outcome of this assessment different treatments selected from MAPK pathway 10 inhibitors, EMT pathway inhibitors, SRC pathway inhibitors, taxanes and anti-angiogenic therapeutic agents may be indicated. Related treatment methods and products are also provided.Type: ApplicationFiled: March 13, 2017Publication date: May 2, 2019Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Aya EL-HELALI, Niamh MCGIVERN, Andrena MCCAVIGAN, Bethanie PRICE, Laura KNIGHT, Nuala MCCABE, Richard KENNEDY, Paul HARKIN, Charlie GOURLEY
-
Patent number: 10260097Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: June 4, 2012Date of Patent: April 16, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10196697Abstract: A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.Type: GrantFiled: December 12, 2014Date of Patent: February 5, 2019Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Steven Walker, Andrena McCavigan, Timothy Davison, Richard Kennedy, Paul Harkin, Laura Hill
-
Publication number: 20170088902Abstract: The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub-type. Companion methods of treating cancer and agents for use in treating cancer are also provided.Type: ApplicationFiled: May 28, 2015Publication date: March 30, 2017Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Denis Paul HARKIN, Richard KENNEDY, Andrena MCCAVIGAN, Katherine KEATING, Laura HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
-
Publication number: 20170073761Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: ApplicationFiled: February 9, 2015Publication date: March 16, 2017Inventors: Denis Paul HARKIN, Richard KENNEDY, Katherine E. KEATING, Andrena MCCAVIGAN, Laura A. HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
-
Publication number: 20160312294Abstract: A method is provided for characterising and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.Type: ApplicationFiled: December 12, 2014Publication date: October 27, 2016Inventors: Steven WALKER, Andrena MCCAVIGAN, Timothy DAVISON, Richard KENNEDY, Paul HARKIN, Laura HILL
-
Publication number: 20160002732Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: December 3, 2013Publication date: January 7, 2016Inventors: Dennis Paul HARKIN, Fionnuala PATTERSON, Claire TRINDER, Eamonn J. O'BRIEN, Caroline MICHIE, Charlie GOURLEY, Laura A. HILL, Katherine E. KEATING, Jude O'DONNELL, Max BYLESJO, Steve DEHARO, Vitali PROUTSKI, Richard KENNEDY, Timothy DAVISON, Andreas WINTER, Andrena MCCAVIGAN
-
Publication number: 20140342924Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: June 4, 2012Publication date: November 20, 2014Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Dennis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan